Surgery Partners outlook, USPI leadership move & more – 5 recent key notes on ASC companies
The $792 million Surgery Partners and Symbion deal is expected to close in the fourth quarter of this year. Moody's Investors Services gave Surgery Partners a 'B3' rating. Moody's attributed its rating to the company's high level of debt, but offered a positive outlook on the company's place in a growing industry. Standard & Poor's Ratings Service predicts moderate cash flow and stable margins, but mentioned the risk of integration on such a large scale.
In the closing of the $2.35 billion Sheridan Healthcare acquisition, AmSurg paid approximately $2.1 billion in cash and issued 5.7 million shares of common stock.
Harold L. Paz, MD, a United Surgical Partners International board member, will join Aetna as executive vice president and chief medical officer.
Hospital Corporation of America stock traded at $62.44 per share during the week of July 14 to 18, up 11.62 percent.
Medical Facilities Corporation announced a cash pay dividend of $Cdn$0.09375 per common share, while will be payable on August 15.
If you have a question, issue or note to suggest on an ASC management and development company please contact Carrie Pallardy at email@example.com or Laura Dyrda at firstname.lastname@example.org.
More Articles on ASC Issues:
9 ASC Joint Venture Operating Agreement Issues That Make or Break the Partnership
6 Recent GI Field Partnerships
6 Must-Reads for ASC Turnaround Success
© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
- SurgCenter Development ASCs performed almost 7k joint replacements in 2016, 96% same-day discharge
- ASC Quality Collaboration report: 9 key benchmarks from Q3 2016
- 7 things for ASC leaders to know for Thursday — Jan. 19, 2017
- North America leads global infection control market with 39.5% market share: 5 takeaways
- 'Nightmare bacteria ' making its way across US facilities baffles researchers: 4 things to know